ECM
PTX

Endurant Capital Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

Endurant Capital Management’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-9,850
Closed -$583K – 104
2015
Q2 		$583K Buy
+9,850
New +$695K 0.17% 82

Other funds holding PTX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
ECP
Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Endurant Capital Management's PTX Position: Q3 2015 in Review

Endurant Capital Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q3 2015, closing a stake of 9,850 shares — an estimated $583K sold.

Endurant Capital Management first reported a position in PTX in Q2 2015 and held it in 1 quarter. The position peaked at $583K in Q2 2015. 104 funds tracked by Wall St. Rank hold PTX as of Q3 2015.

  • Endurant Capital Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q3 2015 after selling out during the quarter.
  • Endurant Capital Management sold 9,850 Pernix Therapeutics Holdings, Inc. shares in Q3 2015, an estimated $583K.
  • Endurant Capital Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2015 and held it in 1 quarter.
  • Endurant Capital Management's Pernix Therapeutics Holdings, Inc. position peaked at $583K in Q2 2015.
  • 104 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q3 2015.

Based on Endurant Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.